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The prerequisite of vascularization to permit tumour development
beyond a threshold size has focused attention on the therapeutic
potential of anti-angiogenic and anti-vascular agents (Hanahan
and Folkman, 1996; Hayes et al, 2000). Cis-CA-4, a tubulin-
binding agent currently undergoing Phase I clinical trials, causes
vascular disruption in some experimental primary and orthotopic
tumours, and in vascularized metastatic tumour deposits (Dark
et al, 1997; Beauregard et al, 1998; Grosios et al, 1999; reviewed
in Griggs et al, 2001). Furthermore, cis-CA-4 inhibits metastasis
of Lewis lung carcinoma. The trans-CA-4 isomer is without effect
on either ectopic primary or metastatic Lewis lung carcinoma
development (Griggs et al, manuscript submitted). Cis-CA-4
differentially affects quiescent and tumour vasculature, as indi-
cated by the greater magnitude of transient changes induced in
vascular pressure and resistance in tumours compared with those
in normal tissues (Tozer et al, 1999). The mechanism of action of
cis-CA-4 remains to be elucidated but it has been hypothesized
that it manifests a selective toxicity for tumour endothelial cells
(Dark et al, 1997), because their proliferative activity renders them
more susceptible to the drug than the quiescent vasculature which
predominates in the adult. The anti-vascular activities of cis-CA-4
have been reported to be specific for tumour vasculature. Here we
examined this hypothesis by investigating whether proliferating
endothelial cells in general are susceptible to CA-4P-mediated
damage by studying its effects in rapidly proliferating, non-tumour
tissue using chemical induction of goitre in mice. 
A number of goitrogens can block thyroid hormone production
leading to a rise in thyroid stimulating hormone (TSH) which
promotes growth of thyroid follicular cells. This induces a co-
ordinated programme of neovascularization in which endothelial
cell proliferation is regulated by pro-angiogenic growth factors,
for example vascular endothelial growth factor (VEGF), derived
from follicular cells (Bidey et al, 1999). Following goitrogen treat-
ment, thyroid growth is induced in rodents within 2 days and
continues at a high rate for about 2 weeks. The weight of the gland
approaches a plateau after about 4 weeks (Wynford-Thomas et al,
1982a; Peter et al, 1991). During the phase of active growth the
mitotic activity in endothelial cells parallels that of epithelial cells
(Wynford-Thomas et al, 1982b) and there is a very large increase
in blood flow through the gland. We have utilized this system to
compare the effects of cis-CA-4 and trans-CA-4 on normal and
hyperplastic (goitrogen-treated) mouse thyroid. 
MATERIALS AND METHODS 
Induction of goitre 
Male 8-week-old C57BL/6J mice (Charles River, UK) were
housed according to institutional guidelines. 3 groups of 8 mice
received drinking water containing 0.2% 3-amino-1,2,4-triazole
(Fluka), 0.5% sodium perchlorate and 0.5% sucrose (BDH);
3 other groups of 7 mice received tap water. 
Combretastatin synthesis and administration 
Both isomers of di-sodium phosphate CA-4 pro-drug were synthe-
sized as previously described (Pettit et al., 1995, 1998; Bedford
et al, 1996; Orsini et al, 1997; Pettit and Rhodes, 1998), dissolved
in saline and filter sterilized. Goitrogen-treated and non-goitrogen-
treated groups of mice were given either cis-CA-4 phosphate,
trans-CA-4 phosphate or no further treatment. CA-4 was adminis-
tered by intraperitoneal injection at a dose of 12.5 mg kg21 every
12 hours from the initiation of goitrogen treatment for 10 days, at
which time all mice were killed by CO2 asphyxiation. The treat-
ment schedule used was selected based on previous studies
(Griggs et al, manuscript submitted) in which a chronic treatment
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regime of 12.5 mg kg21 administered every 12 h by intraperitoneal
injection is highly efficacious in the inhibition of metastatic 
development of Lewis lung carcinoma and manifests no detectable
side effects or toxicity in C57B16/J mice. 
Immunohistochemistry 
Thyroid glands attached to the trachea were removed, fixed in
neutral buffered formalin (Sigma) for 24 h and embedded in
paraffin. 4 mm thick sections were cut at 10 levels through each
gland, taking 10 sections at each level. For each thyroid one
section from each level was stained with von Willebrand factor
(Dako) using an avidin-biotin-horse radish peroxidase technique
with diaminobenzidine as the reporter molecule. All sections were
screened microscopically at 100 ´ magnification by two observers
without knowledge of the treatment groups to which they
belonged. 
RESULTS 
All goitrogen-treated groups showed diffuse thyroid enlargement
with hypertrophic follicular cells, loss of colloid and reduction in
size of follicular lumen, together with loss of the normal central
and peripheral zonation (Figure 1B). All non-goitrogen-treated
groups showed peripheral follicles with flattened epithelial cells,
abundant colloid and more active central follicles (Figure 1A). 
All animals in the cis-CA-4 groups given goitrogen showed
multiple microthrombi either in small veins or capillaries within
the thyroid (Figure 1E–H). No microthrombi were seen in extra-
thyroid vessels or in a range of other normal tissues from the same
animals (data not shown). In a few cases the microthrombi in
capillaries had expanded to bulge into the lumen of an adjacent
follicle, covered by a thin layer of stretched follicular cells. The
incidence of microthrombi was quantified by counting the number
of microthrombi detected in sections from 10 levels from each
gland. The identification of microthrombi in stained sections was
confirmed with von Willebrand factor antibody, which identified
endothelial cells and also showed that the microthrombi contained
the factor (Figure 1E, G, H). The abundant level of von Wille-
brand factor in the microthrombi may have originated from 
activated platelets in addition to damaged endothelial cells. In 
untreated goitre, endothelial cells were clearly identifiable by von
Willebrand staining but were frequently undetectable at the
periphery of microthrombi in cis-CA-4-treated goitres. Micro-
thrombi were identified in the thyroids of all 8 mice treated with
cis-CA-4, and were detected in 49 of 74 sections (66%). The mean
number of microthrombi per goitre was 19.0 in cis-CA-4P-treated
animals (Figure 2). None of the 8 animals treated with trans-CA-4
showed any microthrombi (Figure 1D) or any other change in any
of the 74 sections, apart from those attributable to the goitrogen
treatment. One of the 7 animals receiving goitrogen alone showed
3 microthrombi in 2 levels, no microthrombi were detected in the
remaining 63 sections from this treatment group. We presume that
this low incidence of spontaneously arising vascular disruption in
untreated goitre arises from the hyperproliferative nature of the
tissue. No other abnormalities were seen. 
No microthrombi were seen in any of the mice not given
goitrogen (Figure 2) whether treated with cis-CA-4 (Figure 1C) or
trans-CA-4 (data not shown) or given no treatment (Figure 1A).
All showed the expected normal gland morphology with no
anomalous features. 
DISCUSSION 
The data indicate that cis-CA-4 induces a high frequency of
microthrombus formation in normal thyroid tissue that is undergo-
ing a high rate of proliferation with associated neovascularization.
Thyroid hyperplasia was induced by administration of a
goitrogen: in the absence of this treatment cis-CA-4 had no
detectable effects. The trans isomer of CA-4 was without effect on
either normal thyroid tissue or in developing goitres, and neither
isomer affected other normal tissues. The thyroid responses to
CA-4 were consistent with the reported effects of the 2 isomers on
primary and metastatic tumours in mice. Cis-CA-4 retards
primary tumour growth by a process that involves severe vascular
damage and it is also a potent inhibitor of metastatic development.
The  trans-CA-4 isomer, in contrast, does not inhibit either
primary or secondary tumour development. Cis-CA-4 is a tubulin-
binding agent but, unlike other agents with a similar action, for
example, colchicine and vincristine, its action in vivo appears to
be specifically against endothelial cells. In this study, the damage
to the endothelial cells manifested itself as microthrombi in
venules and capillaries. 
Despite the frequency of microthrombus induction by cis-CA-4,
there was no necrosis in any of the glands and no detectable change
in the degree of hyperplasia in the follicular cells. The thyroid has a
network of capillaries around the follicles and several arteries and
veins which interconnect through this network. Thrombosis in all
the major veins supplying the gland is therefore likely to be neces-
sary before major changes are seen in the gland itself. In a rapidly
growing tumour with new vessels growing into the expanding
neoplasm, thrombosis in the newly formed vessels penetrating the
tumour may well be more effective in causing necrosis or at least in
slowing growth. We have no reason to suppose that vascular
growth in the thyroid due to TSH stimulation differs in any funda-
mental aspect from angiogenesis in other tissues. During goitroge-
nesis vascular growth is coordinated, the thyroid endothelial cells
responding to VEGF, as do endothelial cells of many other tissues,
with VEGF being produced locally by follicular cells in response to
TSH stimulation (Sato et al, 1995; Viglietto et al, 1997; Wang et al,
1998; Bidey et al, 1999). There is no evidence that the endothelial
cells respond directly to TSH. Vascular growth in goitres is there-
fore considered to occur in response to stimulation from epithelial
cells in a way that closely corresponds to angiogenesis in tumours
induced by cancer cells. Goitrogenesis is a highly reproducible
experimental system for inducing vascular growth and the stimu-
lated thyroid gland has one of the highest rates of blood flow of any
tissue. We have shown that the thyroid provides a reproducible in
vivo model system for testing and quantifying the effects of puta-
tive anti-angiogenic or anti-vascular agents in non-tumour tissue.
The demonstration that cis-CA-4 induces widespread micro-
thrombus formation in the rapidly growing vasculature of the
stimulated thyroid indicates that its action is specific not for
tumour vasculature but for growing endothelium. It follows that
the drug may have considerable side effects if any non-neoplastic
vascular proliferation is taking place, for example in inflamma-
tion. We note that the action of cis-CA-4 on hyperplastic, non-
neoplastic vasculature suggests that this drug may be effective
against angioproliferative diseases. 834 J Griggs et al
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Figure 1 Representative histological and immunohistochemical staining of mouse thyroid sections. (A) Section from an untreated mouse, showing normal
thyroid architecture. A portion of the trachea is included (H&E ´ 60). (B) Section from a mouse treated with goitrogen only, showing diffuse thyroid hyperplasia.
Part of the parathyroid is also present (H&E ´ 60). (C) Section from a mouse which was not given goitrogen to induce vascular and epithelial growth, but was
treated with cis CA-4, showing no evidence of thrombi when stained with a rabbit polyclonal antibody (1:500) to von Willebrand factor (vWF) (´ 60). (D) Section
from a mouse treated with goitrogen and trans-CA-4, showing no thrombi (anti-vWF ´ 60). (E) Section from a mouse treated with goitrogen and cis CA-4,
showing multiple thrombi which are positive for vWF (´ 60). (F and G) Higher power photomicrographs from a mouse treated with goitrogen and cis CA-4
showing thrombi (H&E: F) which are positive for vWF (G) in the serial sections (both ´ 120). (H) A higher power photomicrograph from a mouse treated with
goitrogen and cis CA-4, showing a von Willebrand factor-positive thrombus and perifollicular staining of the normal thyroid vasculature (´ 360) Combretastatin affects hyperplastic vasculature 835
British Journal of Cancer (2001) 84(6), 832–835 © 2001 Cancer Research Campaign
Preliminary evidence from Phase I clinical trials (reviewed in
Griggs et al, 2001) suggests that CA-4 exerts an anti-vascular
effect in some human primary tumours. Consistent with rapidly
proliferating endothelium being the primary target of CA-4, we
would speculate that there will be variability in the response of
different tumour types to CA-4 according to the rates of vascular
proliferation, a parameter which shows significant heterogeneity
between tumours. 
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